Platelet MAO inhibition, urinary MHPG, and leukocyte beta-adrenergic receptors in depressed patients treated with phenelzine.
The authors investigated three biochemical indices of peripheral catecholamine activity in 36 depressed inpatients treated with the monoamine oxidase (MAO) inhibitor phenelzine. Platelet MAO activity, urinary excretion of 3-methoxy-4-hydroxyphenylglycol (MHPG), and leukocyte beta-adrenergic receptor functions were measured before and during the 4th week of phenelzine treatment. There were significant reductions in platelet MAO activity, urinary MHPG excretion, and depressive symptoms in all of the patients. Responders had the same decrease in MHPG as nonresponders. There were no changes in leukocyte beta-receptor function in a small subgroup of the patients.
Sharma
R P
RP
Illinois State Psychiatric Institute, Chicago.
Janicak
P G
PG
Javaid
J I
JI
Pandey
G N
GN
Gierl
B
B
Davis
J M
JM
D001792:Blood Platelets / Q000201:enzymology*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D005260:Female; D006018:Glycols / Q000652:urine*; D006801:Humans; D007962:Leukocytes / Q000187:drug effects* / Q000502:physiology; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000652:urine*; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000378:metabolism*; D010624:Phenelzine / Q000494:pharmacology / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D011943:Receptors, Adrenergic, beta / Q000187:drug effects* / Q000502:physiology
D006018:Glycols; D011943:Receptors, Adrenergic, beta; D008734:Methoxyhydroxyphenylglycol; D008995:Monoamine Oxidase; D010624:Phenelzine